{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:21Z","timestamp":1791902661338,"version":"4.3.4"},"reference-count":48,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The efficacy and safety of ritlecitinib, a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, have been demonstrated in the ALLEGRO phase 2b\/3 trial that enrolled patients aged \u2265\u200912\u2009years with alopecia areata (AA) and\u2009\u2265\u200950% scalp hair loss. The present analysis evaluated the cost\u2010effectiveness of ritlecitinib compared with no treatment for patients with AA and\u2009\u2265\u200950% scalp hair loss in Japan from a societal perspective. A Markov model stratified by health states based on the Severity of Alopecia Tool (SALT) was developed to estimate the lifetime costs, including productivity loss, and quality\u2010adjusted life years (QALYs) associated with the treatment of AA. The comparator was no treatment, and clinical parameters were based on the ALLEGRO phase 2b\/3 trial. Costs and QALYs were discounted at an annual rate of 2%, and the incremental cost\u2010effectiveness ratio (ICER) was calculated. Over a lifetime horizon and with the base\u2010case societal perspective, the incremental QALYs and incremental costs of ritlecitinib 50\u2009mg were 1.09 QALYs and 5\u2009262\u2009471 Japanese yen (JPY) (34\u2009766 United States dollars [USD]), respectively. The ICER was 4\u2009816\u2009589 JPY (31\u2009820 USD) per QALY, which was below the cost\u2010effectiveness threshold in Japan of 5\u2009000\u2009000 JPY (33\u2009032 USD) per QALY. A one\u2010way sensitivity analysis showed that parameters with the most notable effect on the ICER were the utility for patients with SALT score\u2009\u2265\u200950, percentage of work time missed due to presenteeism for patients with SALT score\u2009\u2265\u200950, and the discontinuation rate of ritlecitinib 50\u2009mg. These results indicate that ritlecitinib 50\u2009mg is cost\u2010effective compared with no treatment for patients with AA and hair loss on \u2265\u200950% of the scalp from a societal perspective in Japan.<\/jats:p>","DOI":"10.1111\/1346-8138.70212","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:07:23Z","timestamp":1773122843000},"page":"619-631","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost\u2010Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-7231","authenticated-orcid":false,"given":"Akira","family":"Yuasa","sequence":"first","affiliation":[{"name":"Japan Access and Value, Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-5142","authenticated-orcid":false,"given":"Kazumasa","family":"Kamei","sequence":"additional","affiliation":[{"name":"Japan Access and Value, Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Saito","sequence":"additional","affiliation":[{"name":"Health Economic Research Department CRECON Medical Assessment Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mikami","sequence":"additional","affiliation":[{"name":"Japan Access and Value, Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[{"name":"Health Economic Research Department CRECON Medical Assessment Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha Kiyomi","family":"Kurosky","sequence":"additional","affiliation":[{"name":"HTA, Value and Evidence, Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-8008","authenticated-orcid":false,"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[{"name":"HTA, Value and Evidence, Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Japan Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Juntendo Tokyo Koto Geriatric Medical Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243556"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1103442"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.17859"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S53985"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.032"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S245649"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14959"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20628"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16615"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16606"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14311"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16364"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16888"},{"key":"e_1_2_9_15_1","unstructured":"Pfizer Inc. Litfulo (ritlecitinib) Capsules 50 mg https:\/\/www.litfulo.com\/."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)00222\u20102"},{"key":"e_1_2_9_17_1","unstructured":"Ministry of Health Labour and Welfare \u201cCentral Social Insurance Medical Council 2023 August 23 \u201d (2023) https:\/\/www.mhlw.go.jp\/content\/12404000\/001137598.pdf."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6687"},{"key":"e_1_2_9_19_1","first-page":"267","article-title":"Oral Pulse Betamethasone, Methotrexate, and Combination Therapy to Treat Severe Alopecia Areata: A Randomized, Double\u2010Blind, Placebo\u2010 Controlled, Clinical Trial","volume":"20","author":"Asilian A.","year":"2021","journal-title":"Iranian Journal of Pharmaceutical Research"},{"key":"e_1_2_9_20_1","unstructured":"Central Social Insurance Medical Council (552nd) August 23 2023 https:\/\/www.mhlw.go.jp\/content\/12404000\/001137598.pdf."},{"key":"e_1_2_9_21_1","unstructured":"National Institute for Health and Care Excellence \u201c[TA958] Ritlecitinib for Treating Severe Alopecia Areata in People 12\u2009Years and Over \u201d (2024) https:\/\/www.nice.org.uk\/guidance\/TA958."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.09.032"},{"key":"e_1_2_9_23_1","unstructured":"Ritlecitinib Clinical Study Report (Pfizer Data on File 2022)."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010024\u201003645\u20109"},{"key":"e_1_2_9_25_1","unstructured":"Ministry of Health Labour and Welfare \u201cNational Health Insurance Drug Price List (Revised in 2025) \u201d (2025) https:\/\/www.mhlw.go.jp\/topics\/2025\/04\/dl\/tp20250613\u201001_01.pdf."},{"key":"e_1_2_9_26_1","unstructured":"Statistics Bureau of Japan \u201cPatient Survey 2020 \u201d (2020) https:\/\/www.e\u2010stat.go.jp\/stat\u2010search\/files?page=1&layout=datalist&toukei=00450022&tstat=000001031167&cycle=7&tclass1=000001166809&tclass2=000001166811&tclass3=000001166812&tclass4=000001166813&tclass5val=0."},{"key":"e_1_2_9_27_1","unstructured":"Statistics Bureau Ministry of Internal Affairs and Communications \u201cLabour Force Survey 2021 \u201d (2021) https:\/\/www.stat.go.jp\/data\/roudou\/2.html."},{"key":"e_1_2_9_28_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health National Institute of Public Health \u201cGuideline for Preparing Cost\u2010Effectiveness Evaluation to the Central Social Insurance Medical Council \u201d (2024) https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en_2024.pdf."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.10.005"},{"key":"e_1_2_9_30_1","unstructured":"Ministry of Health Labour and Welfare Abridged Life Tables for Japan 2023 https:\/\/www.mhlw.go.jp\/english\/database\/db\u2010hw\/lifetb23\/index.html."},{"key":"e_1_2_9_31_1","unstructured":"Organisation for Economic Co\u2010operation and Development \u201cExchange Rates (Yearly) \u201d (2024) https:\/\/www.oecd.org\/en\/data\/indicators\/exchange\u2010rates.html."},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgf2.422"},{"key":"e_1_2_9_33_1","unstructured":"JMDC Inc JMDC Claims Database https:\/\/www.eng.phm\u2010jmdc.com\/."},{"key":"e_1_2_9_34_1","unstructured":"National Tax Agency Statistical Survey of Actual Status for Salary in the Private Sector 2021 https:\/\/www.nta.go.jp."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.007"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010014\u20100132\u20103"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01300-2"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2515771"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.17234"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000520568"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_2_9_42_1","unstructured":"National Institute for Health and Care Excellence \u201c[TA681] Baricitinib for Treating Moderate to Severe Atopic Dermatitis \u201d (2021) https:\/\/www.nice.org.uk\/guidance\/ta681."},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.2133"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.368"},{"key":"e_1_2_9_45_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health (C2H) National Institute of Public Health (NIPH). [C2H2303] Ritlecitinib (Litfulo Capsule) https:\/\/c2h.niph.go.jp\/results\/C2H2303\/C2H2303_Summary_Eng.pdf."},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03161-3"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roaf113"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16746"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae365"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.70212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:09:29Z","timestamp":1776096569000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.70212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/1346-8138.70212"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.70212","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}